Of the 1,300+ early-stage companies in our pipeline, we’ve invested in 10 — across diagnostics, therapeutics, and other innovations types.

CANCER FUND’s Glimpse program allows our community to review select cancer innovations and provide feedback into our selection process.

Which innovations deserve a closer look? Let us know by reviewing the innovation below.